Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Innovent Biologics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3rd Formulation & Drug Delivery USA

              Participation Not Confirmed

              Update your events

              Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the ESC Annual Conference

              Contact the Supplier

              Lead Product(s): Tafolecimab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2020

              Details:

              Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab (IBI306) were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference.

              PharmaCompass__DigitalAd